Promethera Biosciences

FlandersBio on Twitter

Galapagos NV: business update: http://t.co/6w1jppWE

posted 5 days ago

Social Media

Life Sciences Database

in het nederlands

FlandersBio offers an up-to-date life sciences database containing all the life sciences companies with biotech activity in Flanders, and all FlandersBio members. The guide provides easy and fast access to the local life sciences community.

Website: http://www.promethera.com
Email:
Phone: +32 11 28 69 50
FlandersBio Member
More address details

Business Focus

Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology. Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers.

Company Profile

Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers.

Promethera® Biosciences was founded in 2009 by Sopartec SA, the technology transfer company for the Université Catholique de Louvain and Professor Etienne Sokal, a leading expert in hepatology and cell therapy. In May 2009, Eric Halioua became the Chief Executive Officer of Promethera® Biosciences.

End of October 2009, Promethera® Biosciences has completed a 5.3 million euros A-round of funding.

Science & Technology or Services

Promethera® biosciences’ technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: human Adult Liver-Derived Mesenchymal progenitor/Stem cell (hALDMSC). Promethera® biosciences has developed an innovative technology to isolate and expand the progenitor cell type in order to develop two products: Promethera® HepaStem and Promethera® HepaScreen.

Product description

Promethera® HepaStem is a therapeutic product designed to treat liver diseases by allogeneic liver injection of hALDMSC.
This product has received two orphan drug designations from the European Community for the treatment of Crigler-Najjar syndrome and the treatment of Ornithine transcarbamylase deficiency, an urea cycle disease.
Promethera® HepaScreen is a biotechnology tool designed for metabolic evaluation of new chemical entities.
In vitro differentiated hALDMSC express most of the hepatic markers and functions that could be used by the pharmaceutical companies to evaluate liver metabolism or toxicity of newly synthesized compounds during screening of lead compound optimization.

Alliances

Promethera® Biosciences has signed several research and collaborative agreements with industrial or academic partners:

Academic Partners:
Promethera® Biosciences has entered into a research agreement with Université Catholique de Louvain and the Pediatric Hepatology and Cell Therapy Laboratory on Fulminant Hepatitis and Liver Fibrosis
Promethera® Biosciences has signed a research agreement with the University of Hasselt and Biomed on biomarkers of the Promethera® HepaStem product
Collaborative Project:
Promethera® Biosciences is coordinator of a Collaborative project "ValoStem" which received labelization from BioWin. This project will start in January 2010 and regroups Academic partners (Faculté Notre Dame de la Paix Namur, Université Catholique de Louvain) and Indusdrial Partners (UCB pharma and Promethera Biosciences).

Promethera® Biosciences also received funding from: